

A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa

Christian L. Althaus^{*a}, Stephanie Baggio^{b,c}, Martina L. Reichmuth^{a,d}, Emma B. Hodcroft^{a,e}, Julien Riou^a, Richard A. Neher^{e,f}, Frédérique Jacquerioz^{g,h,i}, Hervé Spechbachⁱ, Julien Salamunⁱ, Pauline Vetter^{g,j}, Carolyn Williamson^{k,l,m}, Nei-yuan Hsiao^{k,l}, Wolfgang Preiserⁿ, Mary-Ann Davies^{o,p}, Richard J. Lessells^{m,q}, Tulio de Olivera^{m,q,r}, Laurent Kaiser^{g,j}, and Isabella Eckerle^g

^aInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

^bDivision of Prison Health, Geneva University Hospitals, Geneva, Switzerland

^cOffice of Corrections, Department of Justice and Home Affairs of the Canton of Zurich, Zurich, Switzerland

^dGraduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland

^eSwiss Institute of Bioinformatics, Basel, Switzerland

^fBiozentrum, University of Basel, Basel, Switzerland

^gGeneva Center for Emerging Viral Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

^hDivision of Tropical and Humanitarian Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

ⁱPrimary Care Division, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

^jLaboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

^kDivision of Medical Virology, Wellcome Centre for Infectious Diseases Research in Africa & the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

^lDivision of Medical Virology at NHLS Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa

^mCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa

ⁿDivision of Medical Virology, University of Stellenbosch / National Health Laboratory Service Tygerberg, Cape Town, South Africa

^oCentre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa

^pWestern Cape Government: Health, Cape Town, South Africa

^qKwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), Department of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban, South Africa

^rDepartment of Global Health, University of Washington, Seattle, USA

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

*Corresponding author: christian.althaus@ispm.unibe.ch

37 ABSTRACT

38 Several SARS-CoV-2 variants of concern (VOC) are spreading rapidly in different regions of
39 the world. The underlying mechanisms behind their transmission advantage remain unclear.
40 We measured viral load in 950 individuals and found that infections with variant Alpha exhibit a
41 higher viral load and longer viral shedding compared to non-VOC. We then used a transmission
42 model to analyze the spread of variant Alpha in Geneva, Switzerland, and variant Beta in South
43 Africa. We estimated that Alpha is either associated with a 37% (95% compatibility interval,
44 CI: 25–63%) increase in transmissibility or a 51% (95% CI: 32–80%) increase of the infectious
45 duration, or a combination of the two mechanisms. Assuming 50% immune evasion for Beta,
46 we estimated a 23% (95% CI: 10–37%) increase in transmissibility or a 38% (95% CI: 15–78%)
47 increase of the infectious duration for this variant. Beta is expected to outgrow Alpha in regions
48 where the level of naturally acquired immunity from previously circulating variants exceeds 20%
49 to 40%. Close monitoring of Alpha and Beta in regions with different levels of immunity will
50 help to anticipate the global spread of these and future variants.

51 INTRODUCTION

52 Novel SARS-CoV-2 variants emerged independently in different geographic regions of the world.
53 According to the definition of the World Health Organization (WHO) as of 25 February 2021,
54 a SARS-CoV-2 variant is defined as a variant of concern (VOC) if it has been demonstrated
55 to be associated with an increase in transmissibility or profound changes in the epidemiology,
56 increased virulence or change in clinical disease presentation; or decrease in effectiveness of
57 public health and social measures or available diagnostics, vaccines, and therapeutics (World
58 Health Organization, 2021). To date, there are four variants identified that fulfill the criteria,
59 namely variant Alpha, first detected in the UK, variant Beta, first detected in South Africa, variant
60 Gamma that emerged in Brazil, and variant Delta, first documented in India. All four variants
61 have become the dominant circulating virus in the affected regions within a short time period,
62 raising concerns about their increased fitness and transmission advantage (Abdool Karim and
63 de Oliveira, 2021).

64 For Alpha, several studies have estimated an increased transmissibility between 40% to
65 100% in the United Kingdom, the United States, Denmark, and Switzerland (Leung et al.,
66 2021; Davies et al., 2021a; Volz et al., 2021; Chen et al., 2021). A higher transmissibility per
67 contact with an infectious person is supported by findings that patients infected with Alpha
68 (or S-gene target failure, SGTF) appear to have lower Ct values (Davies et al., 2021b) and
69 higher viral loads (Ratcliff et al., 2021). A recent study compared 1453 Alpha cases with 977
70 non-Alpha cases and found a 1.0 higher mean \log_{10} viral load and a 2.6 times higher cell culture
71 replication probability in Alpha cases (Jones et al., 2021). However, others found no differences
72 in viral burden for SGTF (Walker et al., 2021). In addition, preliminary data suggest that Alpha
73 could also be associated with extended periods of viral shedding when compared to previously
74 circulating variants (Kissler et al., 2021). In contrast, evasion from naturally acquired immunity
75 seems to play little to no role for the transmission advantage of Alpha as neutralization by both
76 convalescent sera from previous infections, as well as vaccine-derived antibodies, were able to
77 neutralize Alpha in a similar or only slightly reduced manner (Abdool Karim and de Oliveira,
78 2021).

79 The mechanisms of the transmission advantage of Beta are less well understood. While an
80 increased transmissibility and/or a longer infectious duration cannot be ruled out (Pearson et al.,
81 2021), the constellation of mutations in the spike receptor-binding-domain (particularly mutation

82 E484K and K417N) and the N-terminal domain has been associated with escape from mono-
83 clonal antibodies (mAb) and polyclonal serum mediated neutralization (Tegally et al., 2021;
84 Wibmer et al., 2021; Cele et al., 2021; Collier et al., 2021). Gamma, with which Beta shares
85 E484K and other critical mutations, was estimated to evade 21–46% of protective immunity
86 elicited by previous infection with non-VOC (Faria et al., 2021). In order to anticipate the global
87 spread of Alpha, Beta and other variants, it is critically important to understand the consequences
88 of these altered transmission characteristics in different epidemiological settings.

89 In this study, we aimed at better understanding the mechanisms that result in a transmission
90 advantage of Alpha and Beta. First, we measured viral load in 950 individuals infected with
91 either Alpha or non-VOC. Second, we analyzed the increase in the proportion of Alpha in
92 Geneva, Switzerland, and Beta in South Africa using a transmission model. We then estimated
93 the fitness advantage of the two variants considering the following mechanisms: i) increase
94 in transmissibility, ii) increase of infectious duration, and iii) immune evasion. We compared
95 the fitness advantage of both variants at different levels of naturally acquired immunity, and
96 discussed the implications of our findings for anticipating the further spread of these and other
97 SARS-CoV-2 variants.

98 **METHODS**

99 **Data**

100 ***Viral load***

101 We assessed individuals presenting at the outpatient SARS-CoV-2 screening site at the Geneva
102 University Hospitals presenting for routine diagnostic SARS-CoV-2 testing. The majority of
103 patients had symptoms compatible with SARS-CoV-2 infection and a small proportion were
104 asymptomatic contacts. All participants were ≥ 16 years old with suspected SARS-CoV-2
105 infection according to the local governmental testing criteria, i.e., suggestive symptoms for
106 coronavirus disease 2019 (COVID-19) and/or recent exposure to a SARS-CoV-2 positive person.
107 We included only nasopharyngeal swabs (NPS) collected from symptomatic patients with known
108 date of symptom onset. We analyzed all NPS samples using the Cobas® SARS-CoV-2 RT-
109 PCR assay on the 6800 system (Roche), targeting the E and ORF1 gene, or the TaqPath assay
110 (Thermofisher), targeting the N, ORF1, and S gene. To convert Ct values into SARS-CoV-2
111 RNA copy numbers/ml, we performed serial testing of dilutions of cultured SARS-CoV-2, which
112 were quantified by using *in vitro* transcribed RNA obtained from the European Virus Archive by
113 using the Charité E gene assay (Corman et al., 2020; Baggio et al., 2020).

114 From 13 January 2021 to 24 March 2021, we re-screened all positive samples with a
115 diagnostic Ct value ≤ 32 with a single nucleotide polymorphism (SNP) specific RT-PCRs for
116 mutations 501Y and E484K, allowing to assess presence or absence of the mutation by melting
117 curve analysis (VirSNIp SARS Spike 501Y, VirSNIp SARS Spike E484K, TibMolBiol, Berlin).
118 To identify samples belonging to Alpha, we defined presence of the 501Y mutation and absence
119 of the E484K mutation. Next generation sequencing of a subset of positive specimens confirmed
120 that this combination of mutations correlated with Alpha. In order to increase our sample size
121 for the comparison group for non-VOC viruses, we also included patient samples from the same
122 setting tested from 1 October 2020 to 16 December 2020, a time when no VOCs were circulating
123 in Geneva or Switzerland. We excluded all asymptomatic cases, patients with missing values
124 for date of symptom onset, symptom onset > 12 days, other types of material, and a Ct value of
125 initial diagnostic RT-PCR > 32 .

126 **Viral variants**

127 To track the spread of Alpha in Geneva, Switzerland, we relied on the identification of Alpha
128 described above. To cover the period of November and December 2020, we used sequence data
129 from randomly chosen samples from Geneva that were submitted to GISAID by the Swiss SARS-
130 CoV-2 Sequencing Consortium. The data on the proportion of Alpha in Geneva, Switzerland,
131 have been made available on the following website: [https://ispmbern.github.io/
132 covid-19/variants/](https://ispmbern.github.io/covid-19/variants/). For Beta in South Africa, we retrieved all South African SARS-
133 CoV-2 sequences from the GISAID database as of 20 January 2021 ($n = 2986$, collected from 6
134 March 2020 to 6 January 2021) (Shu and McCauley, 2017). We excluded three sequences with
135 unknown collection date, leaving 2983 sequences for analysis.

136 **Model**

Competitive spread between variant and non-variant ('wild-type') strains of SARS-CoV-2 can
be described within the susceptible-infected-recovered (SIR) framework by the following two
ordinary differential equations:

$$\frac{dW}{dt} = \beta SW - \frac{1}{D}W, \quad (1)$$

$$\frac{dV}{dt} = (1 + \tau)\beta(S + \varepsilon(1 - S))V - \frac{1}{(1 + \kappa)D}V, \quad (2)$$

137 where W and V are individuals infected with wild-type and variant, respectively, and S the
138 population of susceptibles. β is the transmission rate and D the infectious duration of the
139 wild-type. The fitness advantage of the variant can act via three different mechanisms:

- 140 1. *Increase in transmissibility*: The transmission rate of the variant is increased by the factor
141 τ .
- 142 2. *Increase of infectious duration*: The infectious duration of the variant is increased by the
143 factor κ .
- 144 3. *Immune evasion*: The variant can partially evade the acquired immunity from previous
145 infections by the wild-type ($1 - S$). Immune evasion can vary from complete cross-
146 protection ($\varepsilon = 0$) to full evasion ($\varepsilon = 1$).

One can show that the proportion of the variant among all infections increases according to
logistic growth (Marée et al., 2000):

$$p(t) = \frac{V(t)}{W(t) + V(t)} = \frac{1}{1 + \mu e^{-\rho t}}, \quad (3)$$

where $\mu = W(0)/V(0)$ and ρ corresponds to the difference in the net growth rates between the
variant and the wild-type:

$$\rho = \frac{dV}{dt} - \frac{dW}{dt} = (1 + \tau)\beta(S + \varepsilon(1 - S)) - \frac{1}{(1 + \kappa)D} - \beta S + \frac{1}{D}. \quad (4)$$

147 Eq. 4 can be solved algebraically for τ , κ or ε . If the transmission advantage acts via a single
148 mechanism only, we obtain the following simplified solutions. First, the increased transmissibility
149 of the variant is given by $\tau = \rho/(\beta S)$, assuming there is no change in the infectious duration
150 and no immune evasion ($\kappa = \varepsilon = 0$). Since the effective reproduction number of the wild-type
151 is $R_w = \beta SD$, we obtain $\tau = \rho D/R_w$. Second, the increased infectious duration of the variant

152 is given by $\kappa = \rho / (1/D - \rho)$, assuming there is no change in transmissibility and no immune
153 evasion ($\tau = \varepsilon = 0$). Finally, assuming there is no change in transmissibility nor the infectious
154 duration ($\tau = \kappa = 0$), the level of immune evasion is given by $\varepsilon = \rho / (\beta\Omega) = \rho D(1 - \Omega) / (\Omega R_w)$,
155 where $\Omega = 1 - S$ corresponds to the proportion of the population with previously acquired
156 immunity against earlier variants, i.e., the cumulative incidence or seroprevalence, at the time
157 the variant starts to grow.

158 We estimated ρ by fitting a logistic growth model (binomial regression) to the proportion
159 $p(t)$ of Alpha in Switzerland, Geneva, and Beta in South Africa. To propagate the uncertainty,
160 we constructed 95% compatibility intervals (CIs) for τ , κ and ε from 10,000 parameter samples
161 of ρ , the generation time D , the effective reproduction number of the wild-type R_w , and the
162 seroprevalence Ω (Amrhein et al., 2019). We assumed a normally distributed generation time
163 with a mean of 5.2 days and a standard deviation of 0.8 days (Figure 1A) (Ganyani et al., 2020).
164 We sampled from publicly available estimates of the daily effective reproduction number based
165 on confirmed cases during the early growth phase of the variants in Geneva, Switzerland, (1
166 November 2020 to 31 January 2021; range: 0.58–1.04) and South Africa (1 September 2020
167 to 31 October 2020; range: 0.90–1.12) (<https://github.com/covid-19-Re>) (Figure
168 1B) (Huisman et al., 2020). In Geneva, Switzerland, seroprevalence was estimated at 21.1%
169 (95% credible interval: 19.2–23.1%; $n = 4,000$) in samples collected from 23 November 2020
170 to 23 December 2020 (Figure 1C) (Stringhini et al., 2021). In South Africa, seroprevalence was
171 estimated at 30.2% (95% CI: 28.8–31.2%; $n = 4,387$) in samples collected from 17 August 2020
172 to 25 November 2020 (Shinde et al., 2021). We ignored vaccine-induced immunity as vaccination
173 uptake was still low during the study periods in both countries. All data and R code files are
174 available on GitHub: <https://github.com/calthaus/sarscov2-variants>.




Figure 1. Parameter distributions of the generation time, effective reproduction number, and seroprevalence. A: Generation time based on Ganyani et al. (2020). B: Effective reproduction number during the early growth phase of the variants (<https://github.com/covid-19-Re>) (Huisman et al., 2020). C: Seroprevalence estimates for Geneva, Switzerland (Stringhini et al., 2021), and South Africa (Shinde et al., 2021).

175 RESULTS

176 We analyzed viral load in a total of 950 specimens from Geneva, Switzerland (604 non-VOC,
177 346 Alpha). We found a higher mean viral load for Alpha compared to non-VOC (7.4 vs. 6.9
178 SARS-CoV-2 log₁₀ RNA copies/ml, $p < 0.001$) (Figure 2A). Analyzing viral load by day post
179 onset of symptoms showed a delayed decrease in viral load for Alpha compared to non-VOC

180 (Figure 2B). Notably, viral load for non-VOC fell below the threshold for presence of infectious
181 (culturable) virus (10^6 SARS-CoV-2 RNA copies/ml) at day 6 to 11. In contrast, viral load
182 remained above that threshold for B.1.1.7 in samples taken from day 6 to 11 post onset of
183 symptoms. Together, these data suggest that Alpha exhibits a transmission advantage that is
184 mediated by either an increased transmissibility or a longer infectious duration, or a combination
185 of both mechanisms.




Figure 2. SARS-CoV-2 viral load for non-VOC and Alpha. A: Comparison of overall viral load. B: Comparison of viral load per day post onset of symptoms. Data: 950 (604 non-VOC, 346 Alpha) individuals from the outpatient screening site at the Geneva University Hospitals, Switzerland. Error bars correspond to the 95% compatibility intervals of the mean. Dashed line: Assumed threshold for presence of infectious virus (10^6 SARS-CoV-2 RNA copies/ml).

186 Alpha was first detected in Geneva, Switzerland, in a sample from 22 December 2020 and
187 almost completely replaced the previously circulating variants by the end of March 2021 (Figure
188 3A). We estimated the logistic growth rate of the proportion of Alpha at 0.065 (95% CI: 0.060–
189 0.071) per day. This corresponds to either a 37% (95% CI: 25–63%) increase in transmissibility
190 or a 51% (95% CI: 32–80%) increase of the infectious duration. As expected, immune evasion
191 alone can be ruled out as an explanation for the observed spread of Alpha as seroprevalence
192 levels in Geneva were not high enough even if evasion was complete (94% of parameter samples
193 resulted in $\epsilon > 1$) (Figures 4B and C).

194 Beta was first detected in South Africa in a sample from 8 October 2020 and practically
195 replaced all previously circulating variants by the end of December 2020 (Figure 3B). We
196 estimated the logistic growth rate of the proportion of Beta at 0.095 (95% CI: 0.085–0.106) per
197 day. This corresponds to either a 49% (95% CI: 34–67%) increase in transmissibility or a 97%
198 (95% CI: 54–187%) increase of the infectious duration. Complete immune evasion alone would
199 require a seroprevalence level of 33% (95% CI: 25–40%) to explain the spread of B.1.351, which
200 is only slightly higher than the estimated level of 30% in South Africa. Nevertheless, since 78%
201 of parameter samples resulted in $\epsilon > 1$ (Figures 4E and F), we conclude that Beta is likely to be
202 associated with an increased transmissibility and/or an increased infectious duration in addition
203 to partial immune evasion.

204 Based on our analysis, it is not possible to quantify the degree of immune evasion for Beta




Figure 3. Increase in the proportion of SARS-CoV-2 variants among confirmed cases. A: Alpha in Switzerland, Geneva. B: Beta in South Africa. Error bars and shaded areas correspond to 95% compatibility intervals of the data (blue) and model (red), respectively.

205 (Figures 4E and F). An analysis of Gamma – which shares E484K with Beta – in Brazil estimates
206 that this variant evades 25–61% of protective immunity elicited by previous infection with other
207 variants (Faria et al., 2021). Assuming 50% immune evasion for Beta, we estimated an additional
208 23% (95% CI: 10–37%) increase in transmissibility or a 38% (95% CI: 15–78%) increase of the
209 infectious duration, which is less than for Alpha without immune evasion (Figures 4E and F).

210 In regions where both Alpha and Beta are present, the existing level of protective immunity
211 against previously circulating variants, i.e., the cumulative incidence or seroprevalence, may
212 influence which variant will outgrow the other, although transmission heterogeneity and other
213 epidemic drivers will mediate this. We estimated the expected growth advantage of both variants
214 as a function of seroprevalence, assuming no immune evasion for Alpha and varying levels of
215 immune evasion for Beta (Figure 5). Depending on the level of immune evasion, Beta is expected
216 to outgrow Alpha when the level of naturally acquired immunity against previously circulating
217 variants exceeds 20% to 40%.

218 DISCUSSION

219 We used clinical and epidemiological data to better understand the mechanisms and implications
220 of the transmission advantage of the SARS-CoV-2 variants Alpha and Beta. We found that Alpha
221 infections exhibit a higher viral load and longer viral shedding compared to non-VOC. Using a
222 transmission model, we estimated that Alpha is either associated with a 37% (95% CI: 25–63%)
223 increase in transmissibility or a 51% (95% CI: 32–80%) increase of the infectious duration.
224 Assuming that Beta results in partial immune evasion, we estimated that Beta exhibits a lower
225 increase in transmissibility and/or the infectious duration compared to Alpha. Nevertheless, our
226 analysis suggests that Beta might be expected to outgrow Alpha in regions where the level of
227 naturally acquired immunity against previously circulating variants exceeds 20% to 40%.

228 A strength of our study is the combination of clinical and epidemiological data to analyze
229 the mechanisms and the epidemiological implications of the transmission advantage of Alpha
230 and Beta. The transmission model allowed us to study the competitive spread between variant
231 and non-variant strains of SARS-CoV-2 within the framework of evolutionary and population
232 biology. We considered multiple uncertainties, such as the underlying epidemic dynamics and




Figure 4. Relationship between increase in transmissibility, increase of infectious duration, and immune evasion. Top row: Alpha in Geneva, Switzerland. Bottom row: Beta in South Africa. Lines and shaded areas correspond to the median and 95% compatibility intervals.




Figure 5. Growth advantage of Alpha and Beta over ‘wild-type’ variants of SARS-CoV-2. For Alpha, we assumed no immune evasion ($\epsilon = 0$), i.e., the growth advantage is constant and independent of the seroprevalence. For Beta, we assumed immune evasion of 25% (A), 50% (B), and 75% (C). The growth advantage is relative to a ‘wild-type’ variant with $R_w = 1$. Lines and shaded areas correspond to the median and 95% compatibility intervals.

233 the level of population immunity.

234 Our study has a number of limitations. First, we inferred specimens from Geneva, Switzer-
 235 land, as being Alpha by using mutation specific RT-PCR only. However, NGS surveillance of
 236 circulating variants in Switzerland confirmed that presence of 501Y was closely correlated with
 237 Alpha. Second, we only included samples with a Ct value ≤ 32 to account for testing selection

238 for mutation specific RT-PCR, so absolute viral loads could be biased towards higher values.
239 Third, the threshold for infectious virus (10^6 SARS-CoV-2 RNA copies/ml) was assessed for
240 non-VOC at the beginning of the pandemic (Wölfel et al., 2020; L’Huillier et al., 2020). As
241 no experimental data on this threshold have been published for Alpha, we assumed that Alpha
242 shows a similar pattern for the presence of culturable virus compared to non-VOC. Fourth, the
243 transmission model did not allow us to quantify the individual contribution of the different
244 mechanisms to the transmission advantage. Fifth, we assumed an exponentially distributed
245 generation time for estimating the increase in transmissibility. A delta distributed generation
246 time would result in slightly higher estimates (Davies et al., 2021a; Volz et al., 2021; Chen et al.,
247 2021). Sixth, estimates of the effective reproduction number based on confirmed cases come with
248 considerable uncertainty. We took this uncertainty into account by sampling from daily estimates
249 over a period of 2 to 3 months. Finally, we used seroprevalence estimates from single studies
250 (South Africa not being based on population representative sampling) and did not consider an
251 increase of seroprevalence during the early growth phase of the variants, heterogeneity across
252 the population, or a potential waning of antibodies.

253 Our findings support the notion that the transmission advantage of Alpha is likely to be
254 mediated via a higher viral load (increase in transmissibility) and/or longer viral shedding
255 (increase of infectious duration). The estimated increase in transmissibility for B.1.1.7 is in good
256 agreement with the lower end of earlier estimates (Leung et al., 2021; Davies et al., 2021a; Volz
257 et al., 2021; Chen et al., 2021). In addition, we also estimated a potential increase of the infectious
258 duration, i.e., the generation time. These findings have important implications for infection
259 control. A higher transmissibility per contact requires an additional reduction in contacts to
260 prevent further spread. In contrast, the transmission advantage of a longer infectious duration
261 could be compensated by early case finding and isolation, particularly in low incidence settings
262 with efficient contact tracing capacities. The typically used isolation period also appears to be
263 sufficient for Alpha, as no considerable increase in SARS-CoV-2 infections among healthcare
264 workers has been reported.

265 Immune evasion is arguably of bigger concern than increases in transmissibility or the in-
266 fectious duration, especially if there is similar evasion of vaccine-elicited immunity. Similar to
267 Gamma, Beta appears to exhibit partial immune evasion. The finding that Beta is not expected
268 to outgrow Alpha in regions where the cumulative incidence of infections with previously cir-
269 culating variants does not exceed 20% is in agreement with the observation that Beta does not
270 seem to replace Alpha in Switzerland or Denmark ([https://cevo-public.github.io/](https://cevo-public.github.io/Quantification-of-the-spread-of-a-SARS-CoV-2-variant)
271 [Quantification-of-the-spread-of-a-SARS-CoV-2-variant](https://www.covid19genomics.dk), [https://www.](https://www.covid19genomics.dk)
272 [covid19genomics.dk](https://www.covid19genomics.dk)). Similarly, it has been shown that Gamma does not seem to be able
273 to outcompete Alpha in Italy (Stefanelli et al., 2021). On the other hand, Alpha might not be
274 able to outcompete Beta in South Africa. Hence, Beta might outgrow Alpha in some areas of
275 Europe that experience a high cumulative incidence of SARS-CoV-2 in 2020.

276 Our study helps to understand the consequences of the altered transmission characteristics
277 of Alpha and Beta in different epidemiological settings. The presented modeling framework,
278 which considers three different mechanisms that result in a transmission advantage of VOCs,
279 can be readily applied to data sets from other regions and countries. More research is needed to
280 better understand how VOCs affect symptomatology and disease severity, and how they respond to
281 cellular and humoral immune responses elicited by natural infection and vaccines. We conclude
282 that the further spread of Alpha and Beta will strongly depend on the level of acquired immunity
283 from previously circulating variants. Hence, it will be important to closely monitor the spread
284 of these and other VOCs in regions with varying levels of naturally acquired immunity and
285 vaccination uptake.

286 Acknowledgments

287 We would like to thank the Network for Genomic Surveillance in South Africa (NGS-SA)
288 which includes the National Health Laboratory Service, the National Institute for Communicable
289 Diseases, the University of Cape Town, Stellenbosch University, the University of Free State, and
290 the KwaZulu-Natal Research Innovation & Sequencing Platform at the University of KwaZulu-
291 Natal.

292 Funding

293 CA received funding from the European Union's Horizon 2020 research and innovation pro-
294 gramme - project EpiPose (No 101003688). CA, RN and EH received funding from the Swiss
295 National Science Foundation (grant 196046). IE received funding from the Swiss National
296 Foundation (grant 196644 and 196383) and the Private HUG Foundation by the Pictet Charita-
297 ble Foundation. NGS-SA was supported by the Strategic Health Innovation Partnerships Unit
298 of the South African Medical Research Council, with funds received from the South African
299 Department of Science and Innovation.

300 Competing interests

301 The authors declare no competing interests.

302 REFERENCES

- 303 Abdool Karim, S. S. and de Oliveira, T. (2021). New SARS-CoV-2 Variants - Clinical, Public
304 Health, and Vaccine Implications. *N Engl J Med*.
- 305 Amrhein, V., Greenland, S., and McShane, B. (2019). Scientists rise up against statistical
306 significance. *Nature*, 567(7748):305–307.
- 307 Baggio, S., L'Huillier, A. G., Yerly, S., Bellon, M., Wagner, N., Rohr, M., Huttner, A., Blanchard-
308 Rohner, G., Loevy, N., Kaiser, L., Jacquerioz, F., and Eckerle, I. (2020). SARS-CoV-2 viral
309 load in the upper respiratory tract of children and adults with early acute COVID-19. *Clin*
310 *Infect Dis*.
- 311 Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S.,
312 Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B.,
313 Gosnell, B. I., Hanekom, W., Moosa, M.-Y. S., Lessells, R. J., de Oliveira, T., Sigal, A.,
314 NGS-SA, and Team, C.-K. (2021). Escape of SARS-CoV-2 501Y.V2 from neutralization by
315 convalescent plasma. *Nature*.
- 316 Chen, C., Nadeau, S., Topolsky, I., Manceau, M., Huisman, J. S., Jablonski, K. P., Fuhrmann, L.,
317 Dreifuss, D., Jahn, K., Beckmann, C., Redondo, M., Kobel, O., Noppen, C., Risch, L., Risch,
318 M., Wohlwend, N., Kas, S., Bodmer, T., Roloff, T., Stange, M., Egli, A., Eckerle, I., Denes, R.,
319 Feldkamp, M., Nissen, I., Santacroce, N., Burcklen, E., Aquino, C., de Gouvea, A. C., Moccia,
320 M. D., Grüter, S., Sykes, T., Opitz, L., White, G., Neff, L., Popovic, D., Patrignani, A., Tracy,
321 J., Schlapbach, R., Dermitzakis, E. T., Harshman, K., Xenarios, I., Pegeot, H., Cerutti, L.,
322 Penet, D., Blin, A., Elies, M., Althaus, C., Beisel, C., Beerwinkel, N., Ackermann, M., and
323 Stadler, T. (2021). Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland.
324 *medRxiv*.
- 325 Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S,
326 S. A., Bassi, J., Pinto, D., Fregni, C. S., Bianchi, S., Tortorici, M. A., Bowen, J., Culap, K.,
327 Jaconi, S., Camerini, E., Snell, G., Pizzuto, M. S., Pellanda, A. F., Garzoni, C., Riva, A.,
328 CITIID-NIHR BioResource COVID-19 Collaboration, Elmer, A., Kingston, N., Graves, B.,
329 McCoy, L. E., Smith, K. G. C., Bradley, J. R., Temperton, N., Lourdes Ceron-Gutierrez, L.,
330 Barcenas-Morales, G., COVID-19 Genomics UK (COG-UK) consortium, Harvey, W., Virgin,

- 331 H. W., Lanzavecchia, A., Piccoli, L., Doffinger, R., Wills, M., Veessler, D., Corti, D., and
332 Gupta, R. K. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
333 *Nature*.
- 334 Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T.,
335 Brünink, S., Schneider, J., Schmidt, M. L., Mulders, D. G., Haagmans, B. L., van der Veer, B.,
336 van den Brink, S., Wijsman, L., Goderski, G., Romette, J.-L., Ellis, J., Zambon, M., Peiris,
337 M., Goossens, H., Reusken, C., Koopmans, M. P., and Drosten, C. (2020). Detection of 2019
338 novel coronavirus (2019-ncov) by real-time rt-pcr. *Euro Surveill*, 25(3).
- 339 Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson,
340 C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T., Gimma, A., Waites,
341 W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., CMMID COVID-19 Working Group,
342 COVID-19 Genomics UK (COG-UK) Consortium, Diaz-Ordaz, K., Keogh, R., Eggo, R. M.,
343 Funk, S., Jit, M., Atkins, K. E., and Edmunds, W. J. (2021a). Estimated transmissibility and
344 impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*.
- 345 Davies, N. G., Jarvis, C. I., CMMID COVID-19 Working Group, Edmunds, W. J., Jewell, N. P.,
346 Diaz-Ordaz, K., and Keogh, R. H. (2021b). Increased mortality in community-tested cases of
347 SARS-CoV-2 lineage B.1.1.7. *Nature*.
- 348 Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. d. S., Mishra, S., Crispim,
349 M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., Hulswit, R. J. G., Franco, L. A. M.,
350 Ramundo, M. S., de Jesus, J. G., Andrade, P. S., Coletti, T. M., Ferreira, G. M., Silva, C.
351 A. M., Manuli, E. R., Pereira, R. H. M., Peixoto, P. S., Kraemer, M. U. G., Gaburo, Jr, N.,
352 Camilo, C. d. C., Hoeltgebaum, H., Souza, W. M., Rocha, E. C., de Souza, L. M., de Pinho,
353 M. C., Araujo, L. J. T., Malta, F. S. V., de Lima, A. B., Silva, J. d. P., Zauli, D. A. G., Ferreira,
354 A. C. d. S., Schnekenberg, R. P., Laydon, D. J., Walker, P. G. T., Schlüter, H. M., Dos Santos,
355 A. L. P., Vidal, M. S., Del Caro, V. S., Filho, R. M. F., Dos Santos, H. M., Aguiar, R. S.,
356 Proença-Modena, J. L., Nelson, B., Hay, J. A., Monod, M., Miscouridou, X., Coupland, H.,
357 Sonabend, R., Vollmer, M., Gandy, A., Prete, Jr, C. A., Nascimento, V. H., Suchard, M. A.,
358 Bowden, T. A., Pond, S. L. K., Wu, C.-H., Ratmann, O., Ferguson, N. M., Dye, C., Loman,
359 N. J., Lemey, P., Rambaut, A., Fraiji, N. A., Carvalho, M. d. P. S. S., Pybus, O. G., Flaxman,
360 S., Bhatt, S., and Sabino, E. C. (2021). Genomics and epidemiology of the p.1 sars-cov-2
361 lineage in manaus, brazil. *Science*.
- 362 Ganyani, T., Kremer, C., Chen, D., Torneri, A., Faes, C., Wallinga, J., and Hens, N. (2020).
363 Estimating the generation interval for coronavirus disease (COVID-19) based on symptom
364 onset data, March 2020. *Euro Surveill*, 25(17).
- 365 Huisman, J. S., Scire, J., Angst, D. C., Neher, R. A., Bonhoeffer, S., and Stadler, T. (2020).
366 Estimation and worldwide monitoring of the effective reproductive number of SARS-CoV-2.
367 *medRxiv*.
- 368 Jones, T. C., Biele, G., Mühlemann, B., Veith, T., Schneider, J., Beheim-Schwarzbach, J.,
369 Bleicker, T., Tesch, J., Schmidt, M. L., Sander, L. E., Kurth, F., Menzel, P., Schwarzer, R.,
370 Zuchowski, M., Hofmann, J., Krumbholz, A., Stein, A., Edelmann, A., Corman, V. M., and
371 Drosten, C. (2021). Estimating infectiousness throughout SARS-CoV-2 infection course.
372 *Science*.
- 373 Kissler, S. M., Fauver, J. R., Mack, C., Tai, C. G., Breban, M. I., Watkins, A. E., Samant, R. M.,
374 Anderson, D. J., Ho, D. D., Grubaugh, N. D., and Grad, Y. H. (2021). Densely sampled
375 viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to
376 non-B.1.1.7 SARS-CoV-2. *medRxiv*.
- 377 Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., and Wu, J. T. (2021). Early transmissibility
378 assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to

- 379 November 2020. *Euro Surveill*, 26(1).
- 380 L’Huillier, A. G., Torriani, G., Pigny, F., Kaiser, L., and Eckerle, I. (2020). Culture-Competent
381 SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. *Emerg*
382 *Infect Dis*, 26(10):2494–2497.
- 383 Marée, A. F., Keulen, W., Boucher, C. A., and De Boer, R. J. (2000). Estimating relative fitness
384 in viral competition experiments. *J Virol*, 74(23):11067–72.
- 385 Pearson, C. A., Russell, T. W., Davies, N., Kucharski, A. J., CMMID COVID-19 working group,
386 Edmunds, W. J., and Eggo, R. M. (2021). Estimates of severity and transmissibility of novel
387 SARS-CoV-2 variant 501Y.V2 in South Africa.
- 388 Ratcliff, J., Nguyen, D., Fish, M., Rhyne, J., Jennings, A., Williams, S., Al-Beidh, F., Bonsall,
389 D., Evans, A., Golubchik, T., Gordon, A. C., Lamikanra, A., Tsang, P., Ciccone, N., Leuscher,
390 U., Slack, W., Laing, E., Mouncey, P. R., Ziyenge, S., Olivera, M., Ploeg, R., Rowan, K. M.,
391 Shankar-Hari, M., Roberts, D. J., Menon, D. K., Estcourt, L., Simmonds, P., and Harvala, H.
392 (2021). Virological and serological characterization of critically ill patients with COVID-19
393 in the UK: a special focus on variant detection. *medRxiv*.
- 394 Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela,
395 M. S. L., Moodley, D., Hanley, S., Fouche, L., Louw, C., Tameris, M., Singh, N., Goga,
396 A., Dheda, K., Grobbelaar, C., Kruger, G., Carrim-Ganey, N., Baillie, V., de Oliveira, T.,
397 Koen, A. L., Lombaard, J. J., Mngqibisa, R., Bhorat, A. E., Benadé, G., Lalloo, N., Pitsi, A.,
398 Vollgraaff, P.-L., Luabeya, A., Esmail, A., Petrick, F. G., Jose, A. O., Foulkes, S., Ahmed,
399 K., Thombrayil, A., Fries, L., Cloney-Clark, S., Zhu, M., Bennett, C., Albert, G., Faust, E.,
400 Plested, J. S., Robertson, A., Neal, S., Cho, I., Glenn, G. M., Dubovsky, F., Madhi, S. A., and
401 (2021). Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351
402 Variant. *medRxiv*.
- 403 Shu, Y. and McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data - from
404 vision to reality. *Euro Surveill*, 22(13).
- 405 Stefanelli, P., Trentini, F., Guzzetta, G., Marziano, V., Mammone, A., Poletti, P., Grané, C. M.,
406 Manica, M., del Manso, M., Andrianou, X., Pezzotti, P., Ajelli, M., Rezza, G., Brusaferrò, S.,
407 Merler, S., and (2021). Co-circulation of SARS-CoV-2 variants B.1.1.7 and P.1. *medRxiv*.
- 408 Stringhini, S., Zaballa, M.-E., Perez-Saez, J., Pullen, N., de Mestral, C., Picazio, A., Pennacchio,
409 F., Wisniak, A., Richard, A., Baysson, H., Loizeau, A., Balavoine, J.-F., Trono, D., Pittet,
410 D., Posfay-Barbe, K., Flahault, A., Chappuis, F., Kherad, O., Vuilleumier, N., Kaiser, L.,
411 Azman, A. S., Guessous, I., and Specchio-COVID19 Study Group (2021). Seroprevalence of
412 anti-SARS-CoV-2 antibodies after the second pandemic peak. *Lancet Infect Dis*.
- 413 Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D.,
414 Pillay, S., San, E. J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail,
415 A., Mohale, T., Glass, A. J., Engelbrecht, S., Van Zyl, G., Preiser, W., Petruccione, F., Sigal,
416 A., Hardie, D., Marais, G., Hsiao, M., Korsman, S., Davies, M.-A., Tyers, L., Mudau, I., York,
417 D., Maslo, C., Goedhals, D., Abrahams, S., Laguda-Akingba, O., Alisoltani-Dehkordi, A.,
418 Godzik, A., Wibmer, C. K., Sewell, B. T., Lourenço, J., Alcantara, L. C. J., Kosakovsky Pond,
419 S. L., Weaver, S., Martin, D., Lessells, R. J., Bhiman, J. N., Williamson, C., and de Oliveira, T.
420 (2021). Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein.
421 *Nature*.
- 422 Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R.,
423 Laydon, D. J., Dabrera, G., O’Toole, Á., Amato, R., Ragonnet-Cronin, M., Harrison, I.,
424 Jackson, B., Ariani, C. V., Boyd, O., Loman, N. J., McCrone, J. T., Gonçalves, S., Jorgensen,
425 D., Myers, R., Hill, V., Jackson, D. K., Gaythorpe, K., Groves, N., Sillitoe, J., Kwiatkowski,
426 D. P., COVID-19 Genomics UK (COG-UK) consortium, Flaxman, S., Ratmann, O., Bhatt, S.,

- 427 Hopkins, S., Gandy, A., Rambaut, A., and Ferguson, N. M. (2021). Assessing transmissibility
428 of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*.
- 429 Walker, A. S., Vihta, K.-D., Gethings, O., Pritchard, E., Jones, J., House, T., Bell, I., Bell, J. I.,
430 Newton, J. N., Farrar, J., Diamond, I., Studley, R., Rourke, E., Hay, J., Hopkins, S., Crook, D.,
431 Peto, T., Matthews, P. C., Eyre, D. W., Stoesser, N., Pouwels, K. B., and (2021). Increased
432 infections, but not viral burden, with a new SARS-CoV-2 variant. *medRxiv*.
- 433 Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B.,
434 Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., Rossouw, T., Boswell,
435 M., Ueckermann, V., Meiring, S., von Gottberg, A., Cohen, C., Morris, L., Bhiman, J. N.,
436 and Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African
437 COVID-19 donor plasma. *Nat Med*.
- 438 Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer,
439 D., Jones, T. C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J.,
440 Ehmann, R., Zwirgmaier, K., Drosten, C., and Wendtner, C. (2020). Virological assessment
441 of hospitalized patients with COVID-2019. *Nature*, 581(7809):465–469.
- 442 World Health Organization (2021). COVID-19 Weekly Epidemiological Update – 25 February
443 2015.